Eldelumab

DB06116Investigational

MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and...

Mechanism: MDX-1100 binds selectively to CXCL10 and blocks CXCL10 induced calcium flux and cell migration.
Curator reviewed
Primary indication: Investigated for use/treatment in ulcerative colitis.Curator reviewed
Code names: BMS-936557 · MDX-1100

Resolves to

Compound

UNII15O91A27I5CAS946414-98-8

Targets

P02778CXCL10

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Eldelumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account